Vol. 6 No. 7 (2026): July
Reimbursement Reviews

Tezepelumab (Tezspire)

decorative image of the issue cover

Published July 21, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses tezepelumab (Tezspire), 210 mg single-use prefilled syringe or pen (110 mg/mL solution) administered by subcutaneous injection.
  • Indication: As an add-on maintenance treatment with INCS in adult patients with severe CRSwNP inadequately controlled by systemic corticosteroids and/or surgery.